Mineralys: Inaasahang pagbabasa ng topline ng Phase 2 ng Explore-OSA sa Q1 2026

Inihayag ng kumpanya na patuloy itong nasa tamang iskedyul upang iulat ang mga resulta ng topline mula sa Phase 2 Explore-OSA trial sa Q1 2026. Sinusuri ng trial ang mga epekto ng lorundrostat sa mga sintomas ng OSA at presyon ng dugo sa mga pasyenteng may hypertension at moderate to severe OSA. Ang pagbabasang ito ay magbibigay ng karagdagang datos na sumusuporta sa profile ng lorundrostat sa hypertension na may mga comorbid na kondisyon.

Mahahalagang fact

Na-file: Ene 6, 2026, 01:05 PM
Kaganapan: Topline na resulta
Direksyon: Neutral
Kumpanya: MLYSMineralys
Asset: lorundrostat
Pinagmulan: SEC 8-K
Kumpiyansa: May source
Kalendaryo: Desisyon ng FDA (PDUFA) · Dis 22, 2026 · Positibo

Sipi mula sa source

EX-99.1 2 mlys202601068kex991.htm EX-99.1 Document Exhibit 99.1 Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 RADNOR, PA – January 6, 2026 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. In addition, the Company announced that its management team will participate in the 15 th LifeSci Partners Corporate Access event taking place January 12-14,

SEC 8-K